| | | I don't usually chase down leads posted on this board for other companies, but this one is just too juicy to not pursue further. Look for another post from me in a bit as I parse through the fog, the brutally intense fog that is CyDy aka CytoDyn.
And here I was annoyed that Bez was not pumping press releases often enough of ongoing clinical trial results, the CyDy CEO is ejaculating press releases every day!
With 7M dollars in the bank vs 1B, wonder which company we should place our bets on, and guess which is which.
Good on you for the laugh and for lending this nugget, here I was bored by the quarantine and am now laughing out loud as I dissect this company.
Granted, CCR5 is a legit target in HIV, and has immune dampening properties. This has been known for over a decade as Pfizer launched a CCR5 antagonist for HIV called Selzentry many years ago, and the side effect profile was impressive, especially for mitigating cancer long-term and the thought was it was due to Selzentry's immune dampening properties.
But to reverse the order and say that drug now cures TNBC, is laughable. Stay tuned, and definitely don't go selling IMMU for CYDN unless you are also willing to wager that Jesus visited the Americas posthumously after his ascension into heaven. Accompanied by angels, no less. |
|
